Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
Sun Min LimSeong-San KangDong Kwon KimSoo-Hwan LeeChun-Bong SynnSujeong BaekSeung Min YangYu Jin HanMi Hyun KimHeekyung HanKwangmin NaYoungtaek KimMi Ran YunSeok-Young KimYoungseon ByeonYoung S KimJii Bum LeeMin Hee HongJoshua C CurtinBharvin PatelIsabelle BergiersKyoung-Ho PyoByoung Chul ChoPublished in: Cancer research communications (2024)
Amivantamab in synergy with pembrolizumab effectively eradicated EGFRHIGHMETHIGH tumor subcluster in the tumor microenvironment of head and neck squamous cell carcinoma and overcame resistance against anti-PD-1 immunotherapy.